川宁生物：三大中间体整体处在满产状态

Core Viewpoint - Chuaning Bio announced that its three major intermediates are operating at full capacity, despite an 8% year-on-year decline in overall shipment volume, with a significant improvement compared to the second quarter [2] Group 1: Company Performance - The company reported that the shipment volume of its products has decreased by approximately 8% compared to the same period last year [2] - However, there has been a noticeable improvement in shipment volume on a quarter-on-quarter basis [2] Group 2: Market Outlook - The price of penicillin products is currently at a historical low, with expectations that the market may see a recovery in demand as outdated production capacity gradually ceases or reduces output [2] - The fourth quarter is anticipated to bring increased demand from downstream markets due to the traditional peak season, potentially leading to a shift from market observation to purchasing [2] - The overall situation for penicillin is expected to trend positively, while the conditions for thiocyanate erythromycin and cephalosporins are projected to remain stable [2]